TARRYTOWN, N.Y. and PARIS , May 20, 2022 /PRNewswire/ — Dupixent is the first and only medicine indicated to treat eosinophilic esophagitis in the United States ; approval granted more than two months ahead of FDA’s Priority Review action date Dupixent 300 mg weekly significantly improved signs

Original Source

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219